ME1 Stock Overview Engages in the development, cultivation, and distribution of recreational and medical cannabis products in Europe, Canada, Australia, and the Asia Pacific. More details
Risk Analysis + 2 more risks
See All Risk Checks {"enabled":false,"variant":{"name":"disabled","enabled":false},"ready":false,"error":null}
Capture your thoughts, links and company narrative
Melodiol Global Health Limited Competitors Price History & Performance
Summary of share price highs, lows and changes for Melodiol Global Health Historical stock prices Current Share Price AU$0.001 52 Week High AU$2.40 52 Week Low AU$0.001 Beta 2.5 1 Month Change 0% 3 Month Change -50.00% 1 Year Change -99.94% 3 Year Change -100.00% 5 Year Change -100.00% Change since IPO -100.00%
Recent News & Updates See more updates Melodiol Global Health Limited has completed a Follow-on Equity Offering in the amount of AUD 3 million. Jun 05
Melodiol Global Health Limited has filed a Follow-on Equity Offering in the amount of AUD 3 million. May 03
Melodiol Global Health Limited (ASX:ME1) Stock's 40% Dive Might Signal An Opportunity But It Requires Some Scrutiny May 01
Melodiol Global Health Limited, Annual General Meeting, May 31, 2024 Mar 28
Investors Give Melodiol Global Health Limited (ASX:ME1) Shares A 59% Hiding Mar 02
New major risk - Negative shareholders equity Mar 01 Melodiol Global Health Limited has filed a Follow-on Equity Offering in the amount of AUD 6 million. Feb 22
Melodiol Global Health Limited Option Expiring 13 November 2028 Deferred Settlement Deleted from OTC Equity Feb 07 Melodiol Global Health Limited has completed a Follow-on Equity Offering in the amount of AUD 0.215 million. Jan 16
Melodiol Global Health Limited Announces Resignation of Erlyn Dawson as Joint Company Secretary Dec 22 Melodiol Global Health Limited has completed a Follow-on Equity Offering in the amount of AUD 0.231808 million. Dec 07
Melodiol Global Health Limited has completed a Follow-on Equity Offering in the amount of AUD 1.022261 million. Nov 29
Melodiol Global Health Limited has completed a Follow-on Equity Offering in the amount of AUD 1.022261 million. Nov 28
Melodiol Global Health Limited has filed a Follow-on Equity Offering in the amount of AUD 1.010906 million. Nov 14
First half 2023 earnings released: AU$0.013 loss per share (vs AU$0.006 loss in 1H 2022) Sep 05 Melodiol Global Health Limited has completed a Follow-on Equity Offering in the amount of AUD 0.574725 million. Aug 14
Panacea Life Sciences Holdings, Inc. (OTCPK:PLSH) entered into a non-binding LOI to acquire Sierra Sages Herbs, LLC and Halucenex Life Sciences Inc. for $20 million. Aug 03
Here's Why Creso Pharma (ASX:CPH) Can Afford Some Debt May 11
Full year 2022 earnings released: AU$0.022 loss per share (vs AU$0.027 loss in FY 2021) Mar 03
Creso Pharma Limited (ASX:CPH) entered into a binding letter of intent to acquire Abby & Finn, LLC for $2.5 million. Jan 27
Creso Pharma Limited Announces Board Changes Dec 01
Less than half of directors are independent Nov 16
Creso Pharma Limited Announces Director Appointments Oct 15
Creso Pharma Limited Announces Board Changes Oct 10
First half 2022 earnings released: AU$0.006 loss per share (vs AU$0.018 loss in 1H 2021) Sep 02
Sierra Sage Secures USD 214,000 Purchase Order from Walmart Sep 02
Creso Pharma Limited (ASX:CPH) signed a non-binding, non-exclusive heads of agreement to acquire Dr Pickles Pty Ltd. May 23
Less than half of directors are independent Apr 27
Creso Pharma Limited, Annual General Meeting, May 31, 2022 Apr 13
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Mar 01 Creso Pharma Limited announced that it expects to receive AUD 5 million in funding Feb 25
Creso Pharma to Develop New Hemp-Based Lozenge Product Feb 11
Creso Pharma Limited Launches New E-Commerce Channels Sep 19
First half 2021 earnings released: AU$0.018 loss per share (vs AU$0.08 loss in 1H 2020) Sep 06
Creso Pharma Limited (ASX:CPH) completed the acquisition of Halucenex Life Sciences Inc. Jul 15
Co-Founder & Non-Executive Chairman recently sold AU$4.5m worth of stock Jul 09
Creso Pharma Limited Launches New Product May 18
Creso Pharma Limited (ASX:CPH) entered into an agreement to acquire Halucenex Life Sciences Inc. CAD 10 million. Mar 15
Creso Pharma Limited Signs Non-Binding Letter of Intent with ImpACTIVE Holdings Ltd Mar 10
Full year 2020 earnings released: AU$0.083 loss per share (vs AU$0.10 loss in FY 2019) Mar 05
Creso Pharma Limited Executes A Non-Binding Letter of Intent with Ceres Natural Remedies Mar 01
Creso Pharma Limited Revises Earnings Guidance for the Fiscal Year 2021 Feb 26
Creso Pharma Limited Announces Distribution Agreement with Route2 Pharm Pvt Ltd Feb 16 CBD Oil legal in Australia - Creso Pharma Limited to benefit
Creso Pharma Limited has announced a Derivatives Offering in the amount of AUD 9.523042 million. Jan 22
Creso Pharma Limited Secures New Purchase Order for its Leading Range of Animal Health Products Anibidiol Jan 20
Creso Pharma Limited Secures First Purchase Order for Animal Health Products in LATAM Dec 21
Creso Pharma Limited Announces TGA Decision to Reschedule CBD Dec 16
New 90-day high: AU$0.23 Dec 08
Creso Pharma Limited Receives New Purchase Orders for Anibidiol® Products Dec 04
Creso Pharma Limited Receives Second Purchase Order from Pharma Dynamics, South Africa Oct 13
Creso Pharma Limited announced that it expects to receive AUD 8.992531 million in funding Oct 07
First half earnings released Sep 02
Creso Pharma Limited Announces CEO, Miri Halperin Wernli to Take Role of Technology, Innovation and Distribution Head Aug 17 Shareholder Returns ME1 AU Pharmaceuticals AU Market 7D 0% 4.5% 1.4% 1Y -99.9% -8.5% 9.9%
See full shareholder returns
Return vs Market: ME1 underperformed the Australian Market which returned 19.4% over the past year.
Price Volatility Is ME1's price volatile compared to industry and market? ME1 volatility ME1 Average Weekly Movement n/a Pharmaceuticals Industry Average Movement 9.6% Market Average Movement 8.0% 10% most volatile stocks in AU Market 16.4% 10% least volatile stocks in AU Market 3.0%
Stable Share Price: ME1's share price has been volatile over the past 3 months compared to the Australian market.
Volatility Over Time: Insufficient data to determine ME1's volatility change over the past year.
About the Company Melodiol Global Health Limited engages in the development, cultivation, and distribution of recreational and medical cannabis products in Europe, Canada, Australia, and the Asia Pacific. It is involved in the development and commercialisation of nutraceutical products; and medical supplies business. The company was formerly known as Creso Pharma Limited and changed its name to Melodiol Global Health Limited in June 2023.
Show more Melodiol Global Health Limited Fundamentals Summary How do Melodiol Global Health's earnings and revenue compare to its market cap? ME1 fundamental statistics Market cap AU$1.13m Earnings (TTM ) -AU$35.52m Revenue (TTM ) AU$18.92m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) ME1 income statement (TTM ) Revenue AU$18.92m Cost of Revenue AU$18.10m Gross Profit AU$817.00k Other Expenses AU$36.34m Earnings -AU$35.52m
Last Reported Earnings
Dec 31, 2023
Earnings per share (EPS) -0.032 Gross Margin 4.32% Net Profit Margin -187.73% Debt/Equity Ratio -232.0%
How did ME1 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/10/31 16:55 End of Day Share Price 2024/08/28 00:00 Earnings 2023/12/31 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github .
Analyst Sources Melodiol Global Health Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
